BACKGROUND: Patients with diabetes who use insulin pumps [continuous subcutaneous insulin infusion (CSII)] undergo surgeries that require postoperative hospital admission. There are no defined guidelines for CSII perioperative use. METHODS: This retrospective single-institution study identified type 1 and type 2 diabetes subjects by electronically searching 2005-2010 anesthesia preoperative assessments for "pump." Surgical cases (n = 92) were grouped according to intraoperative insulin delivery method: (a) CSII continuation of basal rate with/without correctional insulin bolus(es) (n = 53); (b) conversion to intravenous insulin infusion (n = 20); and (c) CSII suspension with/without correctional insulin bolus(es) (n = 19). These groups were compared on mean intraoperative blood glucose (BG) and category of most extreme intraoperative BG. RESULTS: Differences were found on baseline characteristics of diabetes duration (p = .010), anesthesia time (p = .011), proportions receiving general anesthesia (p = .013), and preoperative BG (p = .033). The conversion group had the longest diabetes duration and anesthesia time; it had a higher proportion of general anesthesia recipients and a higher mean preoperative BG than the continuation group. There was no significant difference in mean BG/surgical case between continuation (163.5 ± 58.5 mg/dl), conversion (152.3 ± 28.9 mg/dl), and suspension groups (188.3 ± 44.9 mg/dl; p = .128). The suspension group experienced a greater percentage of cases (84.2%) with one or more intraoperative BG > 179 mg/dl than continuation (45.3%) and conversion (40%) groups Figure 1 groupings (p = .034). CONCLUSIONS: In this limited sample, preliminary findings are consistent with similar intraoperative glycemic control between CSII continuation and CSII conversion to intravenous insulin infusions. Continuous subcutaneous insulin infusion suspension had a greater rate of hyperglycemia. Preoperative differences between insulin delivery groups complicate interpretations of findings.
BACKGROUND:Patients with diabetes who use insulin pumps [continuous subcutaneous insulin infusion (CSII)] undergo surgeries that require postoperative hospital admission. There are no defined guidelines for CSII perioperative use. METHODS: This retrospective single-institution study identified type 1 and type 2 diabetes subjects by electronically searching 2005-2010 anesthesia preoperative assessments for "pump." Surgical cases (n = 92) were grouped according to intraoperative insulin delivery method: (a) CSII continuation of basal rate with/without correctional insulin bolus(es) (n = 53); (b) conversion to intravenous insulin infusion (n = 20); and (c) CSII suspension with/without correctional insulin bolus(es) (n = 19). These groups were compared on mean intraoperative blood glucose (BG) and category of most extreme intraoperative BG. RESULTS: Differences were found on baseline characteristics of diabetes duration (p = .010), anesthesia time (p = .011), proportions receiving general anesthesia (p = .013), and preoperative BG (p = .033). The conversion group had the longest diabetes duration and anesthesia time; it had a higher proportion of general anesthesia recipients and a higher mean preoperative BG than the continuation group. There was no significant difference in mean BG/surgical case between continuation (163.5 ± 58.5 mg/dl), conversion (152.3 ± 28.9 mg/dl), and suspension groups (188.3 ± 44.9 mg/dl; p = .128). The suspension group experienced a greater percentage of cases (84.2%) with one or more intraoperative BG > 179 mg/dl than continuation (45.3%) and conversion (40%) groups Figure 1 groupings (p = .034). CONCLUSIONS: In this limited sample, preliminary findings are consistent with similar intraoperative glycemic control between CSII continuation and CSII conversion to intravenous insulin infusions. Continuous subcutaneous insulin infusion suspension had a greater rate of hyperglycemia. Preoperative differences between insulin delivery groups complicate interpretations of findings.
Authors: Steven V Edelman; Bruce W Bode; Timothy S Bailey; Mark S Kipnes; Rocco Brunelle; Xiaojing Chen; Juan P Frias Journal: Diabetes Technol Ther Date: 2010-08 Impact factor: 6.118
Authors: Girish P Joshi; Frances Chung; Mary Ann Vann; Shireen Ahmad; Tong J Gan; Daniel T Goulson; Douglas G Merrill; Rebecca Twersky Journal: Anesth Analg Date: 2010-10-01 Impact factor: 5.108
Authors: Brenda J Leonhardi; Mary E Boyle; Karen A Beer; Karen M Seifert; Marilyn Bailey; Victoria Miller-Cage; Janna C Castro; Peggy B Bourgeois; Curtiss B Cook Journal: J Diabetes Sci Technol Date: 2008-11
Authors: Michelle L Noschese; Monica M DiNardo; Amy C Donihi; Jolynn M Gibson; Glory L Koerbel; Melissa Saul; Maja Stefanovic-Racic; Mary T Korytkowski Journal: Endocr Pract Date: 2009 Jul-Aug Impact factor: 3.443
Authors: Patricia A Mackey; Bithika M Thompson; Mary E Boyle; Heidi A Apsey; Karen M Seifert; Richard T Schlinkert; Joshua D Stearns; Curtiss B Cook Journal: J Diabetes Sci Technol Date: 2015-06-19
Authors: Bithika M Thompson; Joshua D Stearns; Heidi A Apsey; Richard T Schlinkert; Curtiss B Cook Journal: Curr Diab Rep Date: 2016-01 Impact factor: 4.810